

## **Global Internal and Collaboration Pipeline**



mCRPC



2. DualityBio collaboration, BeiGene has global rights

to initiate the study in China.

commercialization for LY01005

3. Zymeworks/Jazz collaboration, BeiGene has APAC/ex Japan, AU, NZ commercial rights

digit royalties on net sales outside of China. "Initiation activities" refers to clinical activities, approval is obtained

6. Luve collaboration, BeiGene has exclusive Mainland China rights to research, development, manufacture, and

\*For a full list of our commercial products, including in-licensed products, please refer to our most recent 10-K filling

4. Amgen collaboration, BeiGene has China commercial rights and tiered mid-single

5. Leads Biolabs collaboration, BeiGene has ex-China commercial rights



Non-Oncology





Prostate cancer (CN)

Breast cancer (CN)